Companies developing artificial intelligence-based platforms that enable the design of small-molecule and biologic drug candidates have been a focus of biopharma dealmaking in the past year.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser . In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.Generative artificial intelligence burst onto the public stage in 2022 with the remarkable text-generating capabilities of the large-language model ChatGPT.
Absci is also pursuing its own candidates, with its first being an AI-designed antibody against the inflammatory disease target, tumor necrosis factor-like cytokine 1A , which is currently in studies to support an investigational new drug application. The company is hoping to compete with the leaders in the race to bring a TL1A-targeted antibody to market for inflammatory bowel diseases, which has seen three large pharma companies—Merck & Co.
Another company involved in a duo of recent AI-related deals—announced on the same day in January at this year’s JP Morgan conference—is Isomorphic Labs. The company was spun out of Google’s DeepMind subsidiary in 2021 to work on drug discovery applications of AlphaFold, the AI-based protein structure-prediction tool that took the field by storm following its publication in 2021. In one deal, Eli Lilly agreed to pay $45 million upfront and up to $1.
Insilico Medicine made the news this year as well with a publication around its leading pipeline candidate INS018_055, a small-molecule inhibitor of the novel antifibrotic target TRAF2- and NCK-interacting kinase , which was also identified using the company’s end-to-end platform. The compound is currently in a phase 2 trial for idiopathic pulmonary fibrosis—an indication for which new therapies are greatly needed and that has historically seen many failures in drug development.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Microsoft Paint Gets AI-Powered Generative Fill and Erase FeaturesMicrosoft Paint is to receive Adobe Photoshop-style AI features in the form of Generative Fill and Generative Erase.
Read more »
Generative AI & Licensing: A Special ReportHow rights holders can monetize their content as data to train and build large language models
Read more »
On Using ChatGPT And Generative AI To Figure Out If You Have Low IQDr. Lance B. Eliot is a world-renowned expert on Artificial Intelligence (AI) with over 7.8+ million amassed views of his AI columns and been featured on CBS 60 Minutes. As a CIO/CTO seasoned executive and high-tech entrepreneur, he combines practical industry experience with deep academic research.
Read more »
First Insight Launches Generative AI Tool To Transform Customer Feedback Into Actionable InsightsFirst Insight unveils InsightIQ Sentiment, a generative AI-powered solution designed to help retailers and brands analyze consumer feedback at scale. The tool provides deep, actionable insights, enabling teams to make smarter decisions across product assortment, design, and marketing strategies.
Read more »
Generative AI Hackathon Explores Tools For JournalistsA monthly generative AI hackathon called Sundai Club focuses on building useful tools, with a recent session dedicated to exploring applications for journalists. The group brainstormed ideas like tracking political posts on TikTok, automating FOIA requests, and summarizing court hearings, ultimately choosing to develop a tool that helps reporters identify interesting papers posted to the Arxiv.
Read more »
Cerebras Files For The Very First Generative AI IPOI spent over 35 years as a high tech exec at HPE, IBM, and AMD. Now I love to learn and share the amazing hardware and services being built to enable Artificial Intelligence, the next big thing in technology.
Read more »